Spots Global Cancer Trial Database for fludeoxyglucose f 18
Every month we try and update this database with for fludeoxyglucose f 18 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein | NCT00964275 | Thromboembolism Unspecified Adu... | diagnostic proc... fludeoxyglucose... | 18 Years - | University Hospital, Brest | |
| Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | NCT01537107 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... Unspecified Adu... | vismodegib sirolimus positron emissi... computed tomogr... pharmacological... laboratory biom... fludeoxyglucose... | 18 Years - | Mayo Clinic | |
| PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer | NCT00362973 | Breast Cancer | laboratory biom... needle biopsy positron emissi... radionuclide im... fludeoxyglucose... | 18 Years - 120 Years | University of Washington | |
| 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx | NCT00757549 | Head and Neck C... | cetuximab cisplatin TdT-mediated dU... 3'-deoxy-3'-[18... immunohistochem... laboratory biom... fludeoxyglucose... radiation thera... | 18 Years - 120 Years | Mayo Clinic | |
| Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy | NCT00450567 | Lung Cancer | computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer | NCT02287636 | Childhood Cance... | fludeoxyglucose... positron emissi... computed tomogr... positron emissi... magnetic resona... | - 17 Years | Case Comprehensive Cancer Center | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma | NCT01359592 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... R-CHOP regimen laboratory biom... fludeoxyglucose... selective exter... yttrium Y 90 ib... | 18 Years - | SWOG Cancer Research Network | |
| Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial | NCT00316901 | Kidney Cancer Melanoma (Skin) | computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer | NCT00852644 | Lung Cancer | computed tomogr... fludeoxyglucose... hypofractionate... stereotactic ra... | 18 Years - | Boston Medical Center | |
| Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer | NCT00978874 | Cervical Cancer | fludeoxyglucose... fluorine F 18 E... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| PET Scans in Patients With Locally Advanced Breast Cancer | NCT00109785 | Breast Cancer | positron emissi... fludeoxyglucose... iodine I 124 io... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR | NCT02717572 | Solid Tumor, Ad... | Fludeoxyglucose... Positron Emissi... Computerized To... Magnetic Resona... | 18 Years - | Washington University School of Medicine | |
| Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | NCT01462630 | Adult Angiosarc... Recurrent Adult... Stage III Adult... Stage IV Adult ... | pazopanib hydro... laboratory biom... positron emissi... computed tomogr... fludeoxyglucose... | 18 Years - | Fox Chase Cancer Center | |
| Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes | NCT00971789 | Cowden's Diseas... Hamartoma Syndr... | fludeoxyglucose... sirolimus Clinical Videog... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer | NCT02226276 | Bone Metastases HER2-positive B... Liver Metastase... Lung Metastases Recurrent Breas... Soft Tissue Met... Stage IV Breast... | fludeoxyglucose... positron emissi... computed tomogr... trastuzumab copper Cu 64-DO... positron emissi... ado-trastuzumab... laboratory biom... | 18 Years - | City of Hope Medical Center | |
| Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer | NCT00083083 | Lung Cancer | carboplatin cisplatin docetaxel etoposide paclitaxel vinblastine sul... vinorelbine tar... gene expression... positron emissi... fludeoxyglucose... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer | NCT00852644 | Lung Cancer | computed tomogr... fludeoxyglucose... hypofractionate... stereotactic ra... | 18 Years - | Boston Medical Center | |
| PET Scans in Patients With Locally Advanced Breast Cancer | NCT00109785 | Breast Cancer | positron emissi... fludeoxyglucose... iodine I 124 io... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx | NCT00498953 | Head and Neck C... | carboplatin cisplatin docetaxel fluorouracil lapatinib ditos... cytogenetic ana... fluorescence in... in situ hybridi... polymerase chai... reverse transcr... immunohistochem... laboratory biom... conventional su... neoadjuvant the... fludeoxyglucose... radiation thera... | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer | NCT00941070 | Recurrent Cervi... Recurrent Vagin... Stage IB Cervic... Stage II Vagina... Stage IIA Cervi... Stage IIB Cervi... Stage III Cervi... Stage III Vagin... Stage IVA Cervi... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Vagin... Therapy-related... | triapine cisplatin external beam r... quality-of-life... questionnaire a... fludeoxyglucose... positron emissi... computed tomogr... | 18 Years - | National Cancer Institute (NCI) | |
| Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma | NCT00110006 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... positron emissi... fludeoxyglucose... | 18 Years - | Case Comprehensive Cancer Center | |
| PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy | NCT00019565 | Unspecified Adu... | magnetic resona... positron emissi... fludeoxyglucose... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery | NCT02112162 | Rectal Neoplasm... | fludeoxyglucose... positron emissi... magnetic resona... laboratory biom... | 18 Years - | Washington University School of Medicine | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery | NCT00004891 | Colorectal Canc... | chemotherapy computed tomogr... conventional su... neoadjuvant the... positron emissi... radionuclide im... fludeoxyglucose... radiation thera... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer | NCT01789892 | Lung Cancer | methylprednisol... fludeoxyglucose... positron emissi... computed tomogr... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery | NCT00003429 | Cervical Cancer | biopsy computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| 11C Topotecan PET Imaging | NCT00253461 | Lung Cancer Metastatic Canc... Ovarian Cancer Unspecified Adu... | computed tomogr... positron emissi... 11C topotecan fludeoxyglucose... | 18 Years - | Case Comprehensive Cancer Center | |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | NCT00095693 | Anaplastic Thyr... Insular Thyroid... Recurrent Thyro... Stage III Folli... Stage III Papil... Stage IV Follic... Stage IV Papill... | sorafenib tosyl... laboratory biom... pharmacological... fludeoxyglucose... positron emissi... dynamic contras... | 18 Years - | National Cancer Institute (NCI) | |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma | NCT01476410 | Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular S... Stage II Adult ... Stage III Adult... Stage IV Adult ... | brentuximab ved... doxorubicin hyd... vinblastine dacarbazine quality-of-life... DNA analysis RNA analysis fludeoxyglucose... positron emissi... laboratory biom... immunohistochem... polymorphism an... | 60 Years - | Northwestern University | |
| Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer | NCT02059889 | Recurrent Non-s... Stage IIA Non-s... Stage IIB Non-s... Stage IIIA Non-... Stage IIIB Non-... | diffusion-weigh... 4-dimensional c... fludeoxyglucose... FDG-PET | 21 Years - | Virginia Commonwealth University | |
| Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | NCT00085293 | Recurrent Thyro... Stage IVA Folli... Stage IVA Papil... Stage IVB Folli... Stage IVB Papil... Stage IVC Folli... Stage IVC Papil... | Decitabine Iodine I 131 Recombinant thy... Fludeoxyglucose... Positron emissi... | 18 Years - | National Cancer Institute (NCI) | |
| F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer | NCT00602043 | Estrogen Recept... Progesterone Re... Progesterone Re... Recurrent Breas... Stage IV Breast... | F-18 16 alpha-f... fludeoxyglucose... positron emissi... positron emissi... computed tomogr... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma | NCT00004152 | Melanoma (Skin) | iodinated contr... computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx | NCT00757549 | Head and Neck C... | cetuximab cisplatin TdT-mediated dU... 3'-deoxy-3'-[18... immunohistochem... laboratory biom... fludeoxyglucose... radiation thera... | 18 Years - 120 Years | Mayo Clinic | |
| Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies | NCT02070406 | Unspecified Adu... | cyclophosphamid... fludarabine pho... NY-ESO-1 reacti... dendritic cell ... aldesleukin fludeoxyglucose... positron emissi... laboratory biom... | 16 Years - | Jonsson Comprehensive Cancer Center | |
| Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma | NCT00433459 | Lymphoma | cyclophosphamid... dacarbazine prednisolone prednisone procarbazine hy... vincristine sul... fludeoxyglucose... radiation thera... | - 17 Years | Martin-Luther-Universität Halle-Wittenberg | |
| PET-MRI in Diagnosing Patients With Colon or Rectal Cancer | NCT01807117 | Recurrent Colon... Recurrent Recta... Stage IIA Colon... Stage IIA Recta... Stage IIB Colon... Stage IIB Recta... Stage IIC Colon... Stage IIC Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... | positron emissi... computed tomogr... magnetic resona... fludeoxyglucose... | 22 Years - | Case Comprehensive Cancer Center | |
| Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial | NCT00316901 | Kidney Cancer Melanoma (Skin) | computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Sunitinib Malate in Treating Patients With Small Cell Lung Cancer | NCT00953459 | Lung Cancer | sunitinib malat... laboratory biom... fludeoxyglucose... | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies | NCT01697527 | Malignant Neopl... | aldesleukin fludarabine pho... cyclophosphamid... laboratory biom... NY-ESO-1 reacti... dendritic cell ... fludeoxyglucose... positron emissi... | 16 Years - | Jonsson Comprehensive Cancer Center | |
| Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer | NCT02059889 | Recurrent Non-s... Stage IIA Non-s... Stage IIB Non-s... Stage IIIA Non-... Stage IIIB Non-... | diffusion-weigh... 4-dimensional c... fludeoxyglucose... FDG-PET | 21 Years - | Virginia Commonwealth University | |
| Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy | NCT01129206 | Adenocarcinoma ... Adenocarcinomas... Recurrent Esoph... Squamous Cell C... Stage IV Esopha... | pralatrexate docetaxel fludeoxyglucose... positron emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | NCT01462630 | Adult Angiosarc... Recurrent Adult... Stage III Adult... Stage IV Adult ... | pazopanib hydro... laboratory biom... positron emissi... computed tomogr... fludeoxyglucose... | 18 Years - | Fox Chase Cancer Center | |
| Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | NCT00735917 | Adenocarcinoma ... Recurrent Pancr... Stage IV Pancre... | saracatinib pharmacogenomic... pharmacological... positron emissi... fludeoxyglucose... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma | NCT00110006 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... positron emissi... fludeoxyglucose... | 18 Years - | Case Comprehensive Cancer Center | |
| Positron Emission Tomography in Detecting Testicle Cancer | NCT00045045 | Testicular Germ... | positron emissi... fludeoxyglucose... | - | National Cancer Institute (NCI) | |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | NCT00095693 | Anaplastic Thyr... Insular Thyroid... Recurrent Thyro... Stage III Folli... Stage III Papil... Stage IV Follic... Stage IV Papill... | sorafenib tosyl... laboratory biom... pharmacological... fludeoxyglucose... positron emissi... dynamic contras... | 18 Years - | National Cancer Institute (NCI) | |
| Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer | NCT00227539 | Lung Cancer | cisplatin pemetrexed diso... adjuvant therap... therapeutic con... fludeoxyglucose... | 18 Years - 120 Years | University of Washington | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment | NCT01031875 | Bladder Cancer Transitional Ce... Urethral Cancer | pazopanib hydro... fludeoxyglucose... | 18 Years - | National Cancer Institute (NCI) | |
| PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer | NCT02287636 | Childhood Cance... | fludeoxyglucose... positron emissi... computed tomogr... positron emissi... magnetic resona... | - 17 Years | Case Comprehensive Cancer Center | |
| Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein | NCT00964275 | Thromboembolism Unspecified Adu... | diagnostic proc... fludeoxyglucose... | 18 Years - | University Hospital, Brest | |
| Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation | NCT01314677 | Stage IIIA Non-... | positron emissi... fludeoxyglucose... | - | City of Hope Medical Center | |
| Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial | NCT00316901 | Kidney Cancer Melanoma (Skin) | computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | NCT01254591 | Breast Cancer Colorectal Canc... Esophageal Canc... Head and Neck C... Lung Cancer | 18F-fluoromison... fluorescence an... laboratory biom... infrared thermo... magnetic resona... therapeutic con... [18F]-ML-10 fludeoxyglucose... rubidium Rb-82 | - | National Cancer Institute (NCI) | |
| PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery | NCT00003429 | Cervical Cancer | biopsy computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer | NCT01931709 | Male Breast Can... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... | fludeoxyglucose... positron emissi... dynamic contras... laboratory biom... | 18 Years - | University of Washington | |
| PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery | NCT00004891 | Colorectal Canc... | chemotherapy computed tomogr... conventional su... neoadjuvant the... positron emissi... radionuclide im... fludeoxyglucose... radiation thera... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy | NCT00450567 | Lung Cancer | computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer | NCT00983697 | Head and Neck C... | therapeutic con... fludeoxyglucose... | 18 Years - | American College of Radiology Imaging Network | |
| Positron Emission Tomography in Determining Stage of Esophageal Cancer | NCT00004867 | Esophageal Canc... | conventional su... positron emissi... radionuclide im... fludeoxyglucose... chemotherapy Radiotherapy | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer | NCT00852644 | Lung Cancer | computed tomogr... fludeoxyglucose... hypofractionate... stereotactic ra... | 18 Years - | Boston Medical Center | |
| Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer | NCT00227539 | Lung Cancer | cisplatin pemetrexed diso... adjuvant therap... therapeutic con... fludeoxyglucose... | 18 Years - 120 Years | University of Washington | |
| Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder | NCT01222676 | Bladder Cancer | cisplatin gemcitabine hyd... sorafenib tosyl... imaging biomark... laboratory biom... computed tomogr... neoadjuvant the... fludeoxyglucose... | 18 Years - | National Cancer Institute (NCI) | |
| Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer | NCT00550628 | Colorectal Canc... Neoplasm of Unc... | DNA methylation... fluorescence in... gene expression... polymerase chai... protein express... reverse transcr... diagnostic labo... immunoenzyme te... immunohistochem... biopsy therapeutic con... fludeoxyglucose... | 15 Years - | Memorial Sloan Kettering Cancer Center | |
| Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer | NCT01789892 | Lung Cancer | methylprednisol... fludeoxyglucose... positron emissi... computed tomogr... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy | NCT01129206 | Adenocarcinoma ... Adenocarcinomas... Recurrent Esoph... Squamous Cell C... Stage IV Esopha... | pralatrexate docetaxel fludeoxyglucose... positron emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein | NCT00964275 | Thromboembolism Unspecified Adu... | diagnostic proc... fludeoxyglucose... | 18 Years - | University Hospital, Brest | |
| PET Scan in Treating Patients With Metastatic Prostate Cancer | NCT00002981 | Prostate Cancer | positron emissi... fludeoxyglucose... methionine C 11 | 0 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer | NCT01494012 | Recurrent Ovari... Recurrent Ovari... Malignant Tumor... Stage IV Ovaria... Stage IV Ovaria... | stereotactic bo... positron emissi... computed tomogr... questionnaire a... fludeoxyglucose... | 18 Years - | Stanford University | |
| S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma | NCT01359592 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... R-CHOP regimen laboratory biom... fludeoxyglucose... selective exter... yttrium Y 90 ib... | 18 Years - | SWOG Cancer Research Network | |
| PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery | NCT00002930 | Esophageal Canc... Lung Cancer | positron emissi... fludeoxyglucose... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes | NCT00971789 | Cowden's Diseas... Hamartoma Syndr... | fludeoxyglucose... sirolimus Clinical Videog... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer | NCT00227539 | Lung Cancer | cisplatin pemetrexed diso... adjuvant therap... therapeutic con... fludeoxyglucose... | 18 Years - 120 Years | University of Washington | |
| 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR | NCT02717572 | Solid Tumor, Ad... | Fludeoxyglucose... Positron Emissi... Computerized To... Magnetic Resona... | 18 Years - | Washington University School of Medicine | |
| Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies | NCT02070406 | Unspecified Adu... | cyclophosphamid... fludarabine pho... NY-ESO-1 reacti... dendritic cell ... aldesleukin fludeoxyglucose... positron emissi... laboratory biom... | 16 Years - | Jonsson Comprehensive Cancer Center | |
| PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery | NCT00003429 | Cervical Cancer | biopsy computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
